James E. Holden

Publications

• Endres CJ. DeJesus OT. Uno H. Doudet DJ. Nickles JR. Holden JE. Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA. Frontiers in Bioscience. 9:505-12, 2004 Jan 1.
• Sossi V. de la Fuente-Fernandez R. Holden JE. Schulzer M. Ruth TJ. Stoessl J. Changes of dopamine turnover in the progression of Parkinson’s disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. Journal of Cerebral Blood Flow & Metabolism. 24(8):869-76, 2004 Aug.
• Doudet DJ. Holden JE. Raclopride studies of dopamine release: dependence on presynaptic integrity. Biological Psychiatry. 54(11):1193-9, 2003 Dec 1.
• Doudet DJ. Holden JE. Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: effect of methamphetamine. Journal of Cerebral Blood Flow & Metabolism. 23(12):1489-94, 2003 Dec.
• DeJesus OT. Shelton SE. Roberts AD. Nickles RJ. Holden JE. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys. Synapse. 44(4):246-51, 2002 Jun 15.
• Lee CS. Samii A. Sossi V. Ruth TJ. Schulzer M. Holden JE. Wudel J. Pal PK. de la Fuente-Fernandez R. Calne DB. Stoessl AJ. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Annals of Neurology. 47(4):493-503, 2000 Apr.
• Sossi V. Holden JE. Chan G. Krzywinski M. Stoessl AJ. Ruth TJ. Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. Journal of Cerebral Blood Flow & Metabolism. 20(4):653-60, 2000 Apr.
• Chan GL. Holden JE. Stoessl AJ. Samii A. Doudet DJ. Dobko T. Morrison KS. Adam M. Schulzer M. Calne DB. Ruth TJ. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. [Journal Article] Journal of Nuclear Medicine. 40(2):283-9, 1999 Feb.